NCT00121251View on ClinicalTrials.gov

Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 3, 2005

Primary Completion Date

March 14, 2017

Study Completion Date

March 14, 2017

Conditions

Recurrent Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v7Stage IV Renal Cell Cancer AJCC v7

Interventions

DRUG

Capecitabine

Given PO

DRUG

Gemcitabine Hydrochloride

Given IV

DRUG

Sorafenib Tosylate

Given PO

Trial Locations (4)

10016

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

10029

Mount Sinai Hospital, New York

10065

Weill Medical College of Cornell University, New York

10467

Montefiore Medical Center - Moses Campus, The Bronx

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00121251 - Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer | Biotech Hunter | Biotech Hunter